Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-25
    E.g., 2018-09-25

Articles

51726 items
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

ID Biomedical and Third Wave settle litigation

ID Biomedical (IDBE; TSE:IDB) and Third Wave Technologies (Madison, Wis.) settled all litigation regarding their respective single nucleotide polymorphism (SNP) detection technologies (see BioCentury, Sept. 18). In exchange for a $4 million upfront cash...
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

Immuno-Designed Molecules in deal with Medarex

Immuno-Designed Molecules (Paris, France) acquired worldwide rights to use MEDX's MDX-210 bispecific anti-HER-2/neu antibody in connection with cell therapy, plus certain rights to MDX-220 and MDX-447 antibodies in all fields. In exchange, MEDX increased its...
12:00 AM, Oct 23, 2000  |  BC Extra | Clinical News

Pain Therapeutics reports Phase II pain data

In a placebo-controlled Phase IIa study of 300 patients with moderate to severe post-surgical pain, PTIE said that its PTI-555 combination of morphine and low-dose opioid antagonist gave 25 percent more pain relief than morphine....
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

Kellogg takes steps against StarLink contamination

Kellogg, one of the largest U.S. food producers, closed several production lines last week at a plant that makes cereal to ensure that its grain supply does not contain StarLink corn. The StarLink variety is...
12:00 AM, Oct 23, 2000  |  BC Extra | Clinical News

MGI Pharma to start pancreatic cancer Phase III

MOGN said it will begin by year end U.S. Phase III testing of its Irofulven hydroxymethylacylfulvene ( MGI 114) compound in patients with advanced pancreatic cancer with disease progression following treatment with Gemzar gemcitabine. The...
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

Oxigene appoints president

Frederick Driscoll was appointed president of Oxigene (OXGN; SSE:OXGN), which is focused on cancer therapeutics. He was formerly senior vice president of finance and operations at Collagenesis....
12:00 AM, Oct 23, 2000  |  BC Extra | Top Story

ZymoGenetics raises $150 million

Novo Nordisk (NVO) subsidiary ZymoGenetics (Seattle, Wash) raised $150 million in a private round. The move establishes ZymoGenetics, which NVO acquired in 1988, as an independent company. ZymoGenetics had operated as NVO's primary U.S. drug...
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

Karo in discovery deal with Aventis

Karo Bio (SSE:KARO) will provide AVE access to its BioKey high throughput screening assays, for use with AVE's genomics-derived infectious disease targets. KARO said it could receive more than $32 million in the deal if...
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

Protherics in two virtual service deals

Protherics (LSE:PTI) will provide virtual screening services to Zeneca Agrochemicals, the crop protection and plant science business of AstraZeneca, as well as to Cytopia, an Australian biopharmaceutical company. PTI's screening is designed to help discover...
12:00 AM, Oct 23, 2000  |  BC Extra | Company News

Vertex's Agenerase approved in Europe

The European Commission granted marketing approval for VRTX's Agenerase amprenavir protease inhibitor to treat HIV infection/AIDS in combination with other antiretrovirals in protease inhibitor-experienced patients. Glaxo Wellcome (GLX; LSE:GLXO) holds an exclusive license to the...

Pages